News Search Results
Mar 04, 2025, 10:00 ET Trintech Continues to Strengthen Market Leadership, Driving Record-Breaking Sales Bookings
Hospitality Management, Allwyn Entertainment, Binance Asia Services Pte, Cracker Barrel Old Country Store, FrieslandCampina Cheese & Butter, HomeToGo, Insomnia Cookies, KBP Brands, Purdue Federal Credit Union and WK Kellogg Co, to name a few. Trintech's focus on cultivating a game-changing partner
More news about: Trintech
Mar 03, 2025, 19:27 ET Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia
innovative insomnia treatments. Nearly 9.5 million Australians experience symptoms of insomnia with approximately 3.6 million of those considered chronic[3]. Sandoz's extensive reach and expertise in the Australian market will ensures our products are widely accessible to insomnia patients across
More news about: Avecho Biotechnology
Mar 03, 2025, 17:00 ET Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia
innovative insomnia treatments. Nearly 9.5 million Australians experience symptoms of insomnia with approximately 3.6 million of those considered chronic[3]. Sandoz's extensive reach and expertise in the Australian market will ensures our products are widely accessible to insomnia patients across
More news about: Avecho Biotechnology
Mar 03, 2025, 08:30 ET Protega Pharmaceuticals collaborates with Wellgistics Health to support pharmacist education and increase patient access to the first and only FDA-approved abuse-deterrent immediate-release opioid, ROXYBOND™
are dose related and are opioid related adverse reactions. The most frequent of these included nausea, constipation, vomiting, headache, pruritus, insomnia, dizziness, asthenia, and somnolence. DRUG INTERACTIONS Concomitant use of ROXYBOND with a CYP3A4 and CYP2D6 inhibitor, such
More news about: Protega